1μg (R: reducing condition, N: non-reducing condition).
CD300a/LMIR1 Fc Chimera Protein, Human
CD300a/LMIR1 Fc Chimera Protein, Human
Price:
Regular price
$268.00 USD
Regular price
Sale price
$268.00 USD
Unit price
per
For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details
Product Details
Product Details
Product Specification
| Species | Human |
| Synonyms | CLM-8, CMRF-35-H9, CMRF35-H9, CMRF35-H, IRC1, IRC2, IgSF12, IRp60, CMRF35H, IGSF12 |
| Accession | Q9UGN4-1 |
| Amino Acid Sequence | Leu18-Gln178, with C-terminal hIgG1 Fc |
| Expression System | HEK293 |
| Molecular Weight | 45-55kDa (Reducing) |
| Purity | ＞95% by SDS-PAGE |
| Endotoxin | <0.1EU/μg |
| Conjugation | Unconjugated |
| Physical Appearance | Lyophilized Powder |
| Storage Buffer | PBS, pH7.4. |
| Reconstitution | Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation. |
| Stability & Storage | · 12 months from date of receipt, lyophilized powder stored at -20 to -80℃. · 3 months, -20 to -80℃ under sterile conditions after reconstitution. · 1 week, 2 to 8℃ under sterile conditions after reconstitution. · Please avoid repeated freeze-thaw cycles. |
| Reference | 1. Ze Tang, Hongfei Cai, Rui Wang, and Youbin Cui. Overexpression of CD300A inhibits progression of NSCLC through downregulating Wnt/β-catenin pathway. Onco Targets Ther. 2018 Dec 7:11:8875-8883. eCollection 2018. |
Background
CD300A, also known as IRp60, is a type I transmembrane glycoprotein receptor of the CD300 glycoprotein family. It is located on the surface of cell membranes.CD300A is differentially expressed on the surface of various blood cells, including T lymphocytes, B lymphocytes, natural killer (NK) cells, neutrophils, and monocytes, and is involved in the regulation of cell growth, proliferation, apoptosis, differentiation, and immune regulation. Increasing evidences show that CD300A also plays a role in the development of hematological malignancies. Jiang et al revealed that knockdown of CD300A by shRNA interference could inhibit cell growth and division in diffuse large B-cell lymphoma (DLBCL) cells, but has no effect on cell apoptosis.In acute myeloid leukemia (AML), knockdown of CD300A also decreases cell proliferation and migration and induces cell apoptosis. However, whether CD300A plays a role in the progression of solid tumors remains unclear.
Picture
Picture
SDS-PAGE
